Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-LC: Maraviroc and Atorvastatin for Long COVID
NCT06974084Phase 3Not yet recruiting
- Sponsor
- HealthBio
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of maraviroc, atorvastatin in post-COVID-19 condition (PCC), sponsored by HealthBio. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
maravirocatorvastatin
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT06974084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974084.